Why Should You and Your Team Attend?
The 14th Tumor Models Summit Boston is designed specifically for preclinical, translational, and discovery leaders across pharma and biotech who are leveraging next-generation tumor models to accelerate oncology pipelines.
Preclinical & Translational Oncology Scientists
Improve clinical predictivity by selecting and validating the most relevant in vivo, in vitro, and ex vivo models, bridging the gap between preclinical data and clinical outcomes, and overcoming key translatability challenges across modalities and indications
Discovery Biology & Early R&D Teams
Accelerate early-stage decision-making by advancing target validation and lead optimisation with predictive models, integrating complex in vitro and computational approaches earlier, and reducing late-stage attrition through stronger early efficacy and toxicity insights
Biomarker & Translational Medicine Leaders
Strengthen patient stratification and clinical success by identifying and validating predictive biomarkers alongside model development, aligning models with patient biology, and increasing confidence in go/no-go decisions through robust translational data
Leaders in Oncology Innovation (Director+)
Shape high-impact strategy and pipeline direction by benchmarking against peers advancing next-generation modalities, identifying strategic partnerships and outsourcing opportunities, and staying ahead of evolving trends in tumor modeling and translational oncology
Divide & Conquer
Divide across both tracks to capture the full picture, from early discovery through to translational validation, and return with aligned strategies to accelerate your pipeline end-to-end.
Track 1: Applications in Drug Discovery & Screening
Best for: Discovery biology, early R&D, in vitro specialists, computational teams
- Advance organoids, complex in vitro, ex vivo, and in silico models for earlier decision-making
- Improve target validation, screening strategies, and lead prioritisation
- Integrate AI, multi-omics, and high-throughput approaches to accelerate discovery
Walk away with: More predictive, scalable discovery workflows to reduce early-stage attrition and fast-track high-potential assets
Track 2: Applications for Efficacy Evaluation & Biomarker Discovery
Best for: Preclinical, translational, in vivo pharmacology, biomarker teams
- Optimize in vivo and patient-derived models for robust efficacy and toxicology readouts
- Identify and validate biomarkers to predict response and stratify patients
- Strengthen translational alignment between preclinical data and clinical outcomes
Walk away with: Stronger confidence in go/no-go decisions, IND-enabling strategies, and clinical translation
Which Companies Are in Attendance?
Related Events
Explore the Agenda
Study the latest preclinical and translational data on tumor modeling and gain first-hand insight into model selection strategies for in vitro, in vivo, complex in vitro, ex vivo and more.
Partner With Us
Position yourself as the partner of choice amongst the leading East Coast biotech and pharmaceutical companies driving the future of oncology drug development.
Join East Coast Oncology Industry Experts
Connect with experts working across distinctive modalities and align on questions to progress translational decision-making.